Program
surlorian
Also written as “Surlorian”, “S48168 (ARM210)” and “S48168”.
Its studies are mostly in Muscular Diseases · Tachycardia, Ventricular, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Armgo Pharma | 20 open or running | phase 2since Oct 22, 2021 | Oct 24, 2019 | none ahead |
| RyCarma Therapeutics | 11 open or running | phase 2since Apr 7, 2026 | Apr 7, 2026 | Aug 27, 2027phase 2 · NCT07560020 |
Also a collaborator on its studies: celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 24, 2019First study: phase 1 study in Muscular DiseasesNew to Armgo PharmaArmgo Pharma · NCT04141670 · 7 enrolled · United States
- Oct 22, 2021Phase 2 study in Catecholaminergic Polymorphic Ventricular Tachycardia Type 1Armgo Pharma · NCT05122975 · 8 enrolled · United States, Netherlands
- Apr 7, 2026RyCarma Therapeutics's first study: phase 2 study in Autosomal Dominant RYR1-Related MyopathyNew to RyCarma TherapeuticsRyCarma Therapeutics · NCT07560020 · 28 planned · France, Germany, Netherlands and more
Ahead
- Aug 27, 2027Primary completion: phase 2 study in Autosomal Dominant RYR1-Related MyopathyRyCarma Therapeutics · NCT07560020
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07560020Autosomal Dominant RYR1-Related Myopathy · France, Germany, Netherlands and more | 2 | Recruiting | RyCarma Therapeutics | Aug 27, 2027 | 28 |
| NCT05122975Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 · United States, Netherlands | 2 | Terminated | Armgo Pharma | Apr 1, 2024 | 8 |
| NCT04141670Muscular Diseases · United States | 1 | Completed | Armgo Pharma | Dec 30, 2022 | 7 |
How it is read
Names in the registry
- “Surlorian”, 1 entry
- “S48168 (ARM210)”, 1 entry
- “S48168”, 1 entry
Conditions, from the studies’ own filings
- Muscular Diseases, 2 studies
- Tachycardia, Ventricular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.